Get started
Author

Sarath Kanekal

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
2009 · Shannon M. Mumenthaler, Patricia Y.B. Ng, et al. · Molecular Cancer Therapeutics · 142
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
2005 · Hiroshi Yasui, Teru Hideshima, et al. · Blood · 60
S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
2010 · Donald Lavelle, Yogen Saunthararajah, et al. · Journal of Translational Medicine · 30
PDF
Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma
2001 · Tony S. K. Mok, Sarath Kanekal, et al. · Cancer · 30
PDF
In vivo and in vitro cytotoxicity of R ‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells
2006 · Paola Neri, Hiroshi Yasui, et al. · British Journal of Haematology · 18
Circadian pharmacology of l -alanosine (SDX-102) in mice
2006 · Xiao-Mei Li, Sarath Kanekal, et al. · Molecular Cancer Therapeutics · 18
Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report
2019 · Dennis Brown, Zhong-ping Chen, et al. · Glioma · 12
SDX-105 (Treanda™) Enhances the Tumor Growth Inhibitory Effect of Rituximab in Daudi Lymphoma Xenografts.
2004 · Sarath Kanekal, Brian Crain, et al. · Blood · 12
SDX-105 (Bendamustine) inhibits growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID mice
2004 · Sarath Kanekal, Brian Crain, et al. · Cancer Research · 11
Retention of intratumor injections of cisplatinum in murine tumors and the impact on laser thermal therapy for cancer treatment
2008 · Sarath Kanekal, Jayne Joo, et al. · European Archives of Oto-Rhino-Laryngology · 10
Actr-27. Phase 2 Study of Dianhydrogalactitol (val-083) in Patients With Mgmt-unmethylated, Bevacizumab-naïve Recurrent Glioblastoma
2018 · Barbara O’Brien, John de Groot, et al. · Neuro-Oncology · 4
PDF
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
2016 · Kent C. Shih, Manish R. Patel, et al. · Journal of Clinical Oncology · 4
Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
2018 · Kent C. Shih, Manish R. Patel, et al. · Journal of Clinical Oncology · 3
A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.
2023 · Jeffrey A. Bacha, Dennis Brown, et al. · Journal of Clinical Oncology · 2
Abstract CT404: Phase I/II study of VAL-083 in patients with recurrent glioblastoma multiforme
2014 · Kent C. Shih, Manish R. Patel, et al. · Cancer Research · 2
Abstract B252: The unique mechanism of action of VAL-083 may provide a new treatment option for some chemo-resistant cancers.
2013 · Anne Steino, Jeffrey A. Bacha, et al. · Molecular Cancer Therapeutics · 2
383 Preclinical antitumor activity of second generation analogs of SDX-101
2004 · S. Kanekal, B. Crain, et al. · European Journal of Cancer Supplements · 2
VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study
2025 · Chengcheng Guo, Qunying Yang, et al. · Discover Oncology · 1
Abstract LB266: A multicenter phase 1-2a clinical study of Orotecan® (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors
2025 · Jeffrey Bacha, Dennis Brown, et al. · Cancer Research · 1
Abstract 4298: Investigating the potential of EO3001 as a therapeutic agent for clear cell ovarian cancers harboring ARID1A mutations
2025 · Yuchen Ding, Tsz Yin (Jacky) Lam, et al. · Cancer Research · 1
Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors
2022 · James Geller, Patrick Thompson, et al. · Cancer Research · 1
Abstract 1843: Dianhydrogalactitol (VAL-083) for the treatment of glioblastoma multiforme (GBM): Impact of glucose transporters for crossing the blood brain barrier (BBB)
2022 · John M. Langlands, Sarath Kanekal, et al. · Cancer Research · 1
A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.
2022 · Dennis Brown, Jeffrey A. Bacha, et al. · Journal of Clinical Oncology · 1
Ctni-26. Phase 2 Study of Dianhydrogalactitol (val-083) in Patients With Mgmt-unmethylated, Bevacizumab-naïve Glioblastoma in the Recurrent and Adjuvant Setting
2021 · Barbara O'Brien, Marta Penas-Prado, et al. · Neuro-Oncology · 1
PDF
Syst-05. Phase 2 Study of Val-083 and Radiotherapy in Newly Diagnosed Mgmt-unmethylated Gbm
2021 · Zhong-ping Chen, Cheng-cheng Guo, et al. · Neuro-Oncology Advances · 1
Works count: 93
Citation count: 384
H-index: 10
I10-index: 10
Year
Topic
Type